Earnings summaries and quarterly performance for TELA Bio.
Executive leadership at TELA Bio.
Board of directors at TELA Bio.
Research analysts who have asked questions during TELA Bio earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
4 questions for TELA
Also covers: ATEC, AXGN, BVS +10 more
Frank Takkinen
Lake Street Capital Markets
4 questions for TELA
Also covers: ANGO, AORT, AXGN +17 more
MS
Michael Sarcone
Jefferies
4 questions for TELA
Also covers: ALC, AXGN, CTSO +11 more
DT
David Turkaly
Citizens JMP
2 questions for TELA
Also covers: AXGN, FNA, HAE +4 more
Daniel Stauder
Citizen JMP
1 question for TELA
Also covers: AORT, ATRC, AVNS +2 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for TELA
Also covers: APYX, ATEC, ATRC +18 more
SM
Samantha Munoz
Piper Sandler Companies
1 question for TELA
Also covers: ATEC, CVRX, PEN +1 more
Recent press releases and 8-K filings for TELA.
TELA Bio Discusses Growth Trajectory, Financial Position, and 2026 Outlook
TELA
Guidance Update
Hiring
Product Launch
- TELA Bio, currently an $80 million business, aims to grow to $100 million, $130 million, and eventually over $200 million.
- The company ended Q3 with approximately $30 million in cash and has access to a total of $65 million-$70 million through a debt facility and a recent equity raise, believing this positions them to avoid future capital raises.
- TELA Bio provided guidance for at least 15% revenue growth in 2026 and plans to fully upgrade its sales force to 90 representatives by the end of Q1 2026. A cohort of 52 experienced reps achieved 100% of quota with average annual sales of about $1 million per rep.
- Sales and marketing spend has decreased from 93% to 70%-73% of sales, indicating improved efficiency.
- New product launches are anticipated, including a long-term resorbable polymer product for hernia in the first half of 2026 and two plastic and reconstructive products in the second half of 2026.
Dec 3, 2025, 7:30 PM
TELA Bio Outlines Growth Plans and Financial Position
TELA
Guidance Update
Product Launch
Hiring
- TELA Bio, currently an $80 million business, aims to grow into a $200 million-plus business.
- The company anticipates at least 15% revenue growth in 2026.
- TELA Bio plans to expand its sales force from 76 reps to 90 reps by the end of Q1 2026, with a cohort of 52 experienced reps averaging $1 million in annual sales.
- New product launches include a hernia product in H1 2026 and two plastic and reconstructive products in H2 2026.
- The company ended Q3 with $30 million in cash and, after recent financing activities, has approximately $56 million, with an additional $10 million available in Q1 2027, which is expected to be sufficient to avoid further fundraising.
Dec 3, 2025, 7:30 PM
TELA Bio Discusses Growth Strategy, Financial Position, and Product Pipeline
TELA
Guidance Update
Product Launch
Debt Issuance
- TELA Bio, currently an $80 million business, aims to grow significantly, targeting $200+ million in the future, having initiated commercialization around 2020.
- The company projects at least 15% revenue growth for next year (2026), supported by new product launches in 2026 and an expanded sales force, with a goal of 90 reps by the end of Q1 2026.
- TELA Bio ended Q3 with $29 million in cash and, following recent debt and equity raises, has approximately $56 million available, with an additional $10 million debt tranche accessible in Q1 2027, aiming to avoid further fundraising.
- Sales and marketing spend has improved, decreasing from 93% to 70%-73% of sales.
Dec 3, 2025, 7:30 PM
TELA Bio, Inc. Announces Registered Direct Offering and Warrant Issuance
TELA
- TELA Bio, Inc. announced an underwritten registered direct offering of 4,189,000 shares of common stock at $1.11 per share and pre-funded warrants to purchase up to 7,523,000 shares at $1.1099 per share.
- The offering is expected to generate approximately $11.9 million in net proceeds for the company and is anticipated to close on November 17, 2025.
- The company intends to use the proceeds from the offering for general corporate purposes, including sales and marketing, research and development, and working capital.
- Separately, TELA Bio, Inc. issued a warrant to Perceptive Credit Holdings V, LP to purchase 2,000,000 shares of common stock at an exercise price of $1.11 per share.
Nov 14, 2025, 9:38 PM
TELA Bio Reports Q3 2025 Results, Strengthens Balance Sheet, and Provides 2026 Guidance
TELA
Earnings
Guidance Update
Debt Issuance
- TELA Bio reported Q3 2025 revenue of $20.7 million, representing 9% growth over the prior year and marking the third consecutive quarter of sequential growth in 2025.
- The company significantly strengthened its balance sheet by refinancing and upsizing its debt facility from $40 million to $60 million and completing a $13 million equity offering, which together add approximately $26 million in incremental net cash.
- Sales and marketing expenses as a percentage of revenue improved from 89.7% in Q1 to 73.6% in Q3 2025, demonstrating increased operational efficiency.
- TELA Bio expects full-year 2025 revenue to grow at least 16% over 2024 and anticipates full-year 2026 revenue to grow at least 15% from 2025.
- The company reached its 2025 budgeted commercial headcount target of 76 territory managers and plans to expand to 90-plus in Q1 2026, while maintaining a target of high $20 million per quarter for operational break-even.
Nov 13, 2025, 9:30 PM
TELA Bio Prices Underwritten Registered Direct Offering
TELA
- TELA Bio, Inc. announced the pricing of an underwritten registered direct offering of common stock and pre-funded warrants.
- The offering includes 4,189,000 shares of common stock priced at $1.11 per share and 7,523,000 pre-funded warrants at an offering price of $1.1099 per warrant.
- The gross proceeds to TELA from the offering are expected to be approximately $13.0 million, assuming no exercise of the pre-funded warrants.
- The offering was led by Nantahala Capital and EW Healthcare Partners, with Canaccord Genuity acting as the sole bookrunner.
- TELA intends to use the net proceeds for general corporate purposes, including sales and marketing, research and development activities, and working capital.
Nov 13, 2025, 9:21 PM
TELA Bio Reports Q3 2025 Financial Results and Refinances Credit Facility
TELA
Earnings
Guidance Update
Debt Issuance
- TELA Bio reported revenue of $20.7 million for the third quarter ended September 30, 2025, marking a 9% increase from the same period in 2024.
- The company revised its full year 2025 revenue guidance to project at least 16% growth over full year 2024.
- Net loss for Q3 2025 was $8.6 million, and cash and cash equivalents stood at $29.7 million as of September 30, 2025.
- TELA Bio strengthened its capital position by closing a credit facility for up to $70.0 million with Perceptive Advisors, which included an initial loan of $60.0 million.
Nov 13, 2025, 9:08 PM
TELA Bio Reports Q3 2025 Financial Results and Upsizes Credit Facility
TELA
Earnings
Guidance Update
Debt Issuance
- TELA Bio reported revenue of $20.7 million for the third quarter ended September 30, 2025, representing a 9% increase from the same period in 2024.
- The company revised its full-year 2025 revenue guidance to project at least 16% growth over full year 2024.
- Net loss for the third quarter of 2025 was $8.6 million, compared to a net loss of $10.4 million in the same period in 2024.
- TELA Bio strengthened its capital position by closing on a new credit facility for up to $70.0 million with Perceptive Advisors, including an initial $60.0 million loan received subsequent to the end of the third quarter.
Nov 13, 2025, 9:01 PM
Quarterly earnings call transcripts for TELA Bio.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more